Bevacizumab Plus mFOLFOX6 Versus mFOLFOX6 Alone as First-Line Treatment for RAS Mutant Unresectable Colorectal Liver-Limited Metastases: The BECOME Randomized Controlled Trial.

Wentao Tang,Li Ren,Qing-Hai Ye,Ye Wei,Guodong He,Qi Lin,Xiao-Ying Wang,Mingliang Wang,Fei Liang,Yuehong Cui,Tianshu Liu,Jianmin Xu

Bevacizumab Plus mFOLFOX6 Versus mFOLFOX6 Alone as First-Line Treatment for RAS Mutant Unresectable Colorectal Liver-Limited Metastases: The BECOME Randomized Controlled Trial.

2020

Wentao Tang
Li Ren
Qing-Hai Ye
Ye Wei
Guodong He
Qi Lin
Xiao-Ying Wang
Mingliang Wang
Fei Liang
Yuehong Cui
Tianshu Liu
Jianmin Xu

PURPOSETo assess the effects of bevacizumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) as first-line treatment of RAS mutant unresectable colorectal liver metastases.METHODS...

Keywords:

Oxaliplatin
Medicine
Oncology
Bevacizumab
Randomized controlled trial
Mutant
Fluorouracil
Internal medicine
first line treatment

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations